Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum

Earnings Report Was Preempted By C-Suite Change-Up

 
• By Mandy Jackson

Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.

Achievement of each set goal
With many new drugs launched, now BMS must meet several big sales targets • Source: Shutterstock

More from Executives On The Move

More from Leadership